Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 89

Results For "markets"

1111 News Found

Advent to acquire controlling stake in Avra Labs
News | January 24, 2022

Advent to acquire controlling stake in Avra Labs

Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh


Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021


Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool
News | January 20, 2022

Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool

They will commercialize molnupiravir in the international markets


Lupin ties up with Foncoo of China
News | January 19, 2022

Lupin ties up with Foncoo of China

This is the company’s first partnership arrangement in China


Sauri Gudlavalleti is the new Chief Operating Officer of Sai Life Sciences
People | January 19, 2022

Sauri Gudlavalleti is the new Chief Operating Officer of Sai Life Sciences

He holds nine US patents and has published in multiple peer-reviewed journals and conferences


We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure
interviews | January 17, 2022

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment


Outlook for the Indian Pharma Industry remains stable for this year
Opinion | January 13, 2022

Outlook for the Indian Pharma Industry remains stable for this year

The stability is led by healthy demand in the domestic and emerging markets


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies